表紙
市場調査レポート

中国の大量非経口投与(LVP)産業レポート

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

発行 ResearchInChina 商品コード 290582
出版日 ページ情報 英文 65 pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
中国の大量非経口投与(LVP)産業レポート China Large Volume Parenteral (LVP) Industry Report, 2013-2015
出版日: 2013年11月26日 ページ情報: 英文 65 pages
概要

中国の医療改革と製薬市場の持続的発展を背景に、大量非経口投与(LVP)医薬品の生産高と需要は、年々成長を遂げています。

当レポートでは、中国の大量非経口投与(LVP)産業について調査分析し、産業の発展、セグメント別の市場分析を提供するほか、主要企業プロファイルなどを含めて、概略以下の構成でお届けいたします。

第1章 大量非経口投与(LVP)の概要

  • 定義と分類
  • 産業チェーン

第2章 中国のLVP産業の発展の概要

  • 現状
  • 競合パターン
  • 製品構造
  • 地域分布

第3章 中国のLVP市場セグメント

  • 体液バランスの注射
  • 治療の注射
  • 栄養注射
  • 血液量増加の注射
  • 腹膜透析液

第4章 主要企業

  • Kelun Pharma
  • China Resources Double-Crane
  • Fengyuan Pharmaceutical
  • Huaren Pharmaceutical
  • Southwest Pharmaceutical
  • Lijun International Pharmaceutical (Holding)
  • Jinjian Cereals
  • その他

第5章 中国のLVP産業の概要と発展予測

  • 市場規模は上昇、生産能力は低下
  • 産業集中は改善、競争力のある大企業
  • 製品構造はアップグレード、新製品の開発

関連企業

図表

目次
Product Code: ZYM050

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese preparations have grown year by year. In 2006-2012, China's injection output presented the CAGR of 19.2%. However, due to the low barriers to entry, China has seen some signs of the surplus injection capacity, which exceeds the demand by roughly 40%.

Overcapacity and fierce competition are caused by the irrational injection product structure and homogeneity. For example, the output and sales volume of fluid balance injection products with low added value account for 89% of the injection market, but the sales revenue only shares 47%. At the same time, the market demand for amino acids, fat emulsion dual-chamber bags, fat emulsion, total parenteral nutrition, hydroxyethyl starch and unique traditional Chinese medicine injection is quite strong.

Compared to Europe and other developed countries, the concentration degree of Chinese LVP market is still lower. At present, 200 ones of 400 qualified Chinese LVP enterprises run business soundly. By output, the top 10 Chinese companies contribute about 65%; in terms of sales revenue, they devote about 40 %.

Like other chemical preparation segments, Chinese high-end LVP market is still dominated by foreign pharmaceutical companies such as Japan Otsuka, Germany Fresenius Kabi, and USA Baxter.

image1

Take fat emulsion products for example. Fat emulsion is imported by China frequently as a blood and hematopoietic system drug in recent years, with its import volume having been at the high level of typical urban hospitals in 22 Chinese cities for consecutive years. Particularly, the procurement value of moderate and long-chain fat emulsion imported by Chinese typical hospitals hit RMB354million. In China, fat emulsion injection suppliers include Kelun Pharma, Sino-Swed Pharmaceutical Corp, Ltd. (under Fresenius Kabi) and Guangzhou Baxter Qiaoguang (under Baxter) with the respective output of 14.19 million bottles/bags, 8.1 million bottles / bags (including medium/long-chain fat emulsion) and 5.69 million bottles/bags (medium/long-chain fat emulsion) in 2012.

The report highlights the followings:

  • Status quo, competition patterns, product structure, regional distribution and development forecast of Chinese LVP market;
  • Status quo and competition patterns of fluid balance injection, therapeutic injection, nutrition injection, injection for blood volume expansion and peritoneal dialysis fluid injection and other market segments;
  • Operation, LVP business and prospects of 10 companies including Kelun Pharma, China Resources Double-Crane, Fengyuan Pharmaceutical, Huaren Pharmaceutical, Southwest Pharmaceutical and Lijun International Pharmaceutical.

Table of Contents

1 Overview of LVP

  • 1.1 Definition and Classification
  • 1.2 Industry Chain

2 Overview of China LVP Industry Development

  • 2.1 Status Quo
  • 2.2 Competition Pattern
  • 2.3 Product Structure
  • 2.4 Regional Distribution

3 Chinese LVP Market Segments

  • 3.1 Injection for Fluid Balance
  • 3.2 Therapeutic Injection
  • 3.3 Nutritious Injection
    • 3.3.1 Fructose Injection
    • 3.3.2 Amino Acid Injection
    • 3.3.3 Fat Emulsion Injection
  • 3.4 Injection for Blood Volume Expansion
    • 3.4.1 Dextran Injection
    • 3.4.2 Hydroxyethyl Starch Injection
  • 3.5 Peritoneal Dialysis Solution

4 Main Companies

  • 4.1 Kelun Pharma
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Revenue Structure
    • 4.1.4 Gross Margin
    • 4.1.5 Clients and Suppliers
    • 4.1.6 R & D and Investment
    • 4.1.7 LVP Business
    • 4.1.8 Development Forecast
  • 4.2 China Resources Double-Crane
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 Gross Margin
    • 4.2.5 Major Clients
    • 4.2.6 LVP Business
    • 4.2.7 Development Forecast
  • 4.3 Fengyuan Pharmaceutical
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 Gross Margin
    • 4.3.5 Clients and Suppliers
    • 4.3.6 LVP Business
    • 4.3.7 Development Forecast
  • 4.4 Huaren Pharmaceutical
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Gross Margin
    • 4.4.5 Clients and Suppliers
    • 4.4.6 R & D and Investment
    • 4.4.7 Development Forecast
  • 4.5 Southwest Pharmaceutical
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Revenue Structure
    • 4.5.4 Gross Margin
    • 4.5.5 Major Clients
    • 4.5.6 LVP Business
    • 4.5.7 Development Forecast
  • 4.6 Lijun International Pharmaceutical (Holding)
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Shijiazhuang No.4 Pharmaceutical
  • 4.7 Jinjian Cereals
    • 4.7.1 Profile
    • 4.7.2 Operation
    • 4.7.3 Jinjiang Phamaceutical
  • 4.8 Other Companies
    • 4.8.1 Qingzhou Yaowang Medicine
    • 4.8.2 Jilin Dubang Pharmaceutical
    • 4.8.3 Shandong Lukang Cisen Pharmaceutical
    • 4.8.4 China Otsuka Pharmaceutical

5 China LVP Industry Summary and Development Prediction

  • 5.1 Market Size to Ascend but Capacity Growth to Slow Down
  • 5.2 Industry Concentration to Improve and Large Players with Obivious Competitive Edges
  • 5.3 Product Structure to Upgrade and New LVP Products Development to be Trend

Related Companies

  • Hunan Jinjian Cereals Industry Co.,Ltd.(600127.SH)
  • Southwest Pharmaceutical Co.,Ltd.(600666.SH)
  • Anhui Fengyuan Pharmaceutical Co.,Ltd.(000153.SZ)
  • Sichuan Kelun Pharmaceutical Co., Ltd.(002422.SZ)
  • Qingdao Huaren Pharmaceutical Co.,Ltd.(300110.SZ)
  • Beijing Double-Crane Pharmaceutical Co.,Ltd.(600062.SH)

Selected Charts

  • Classification, Application and Commodities of LVP (by Clinical Use)
  • LVP Industry Chain
  • LVP Output and YoY Growth Rate in China, 2008-2012
  • Competition Patterns of Chinese LVP Companies (by Output), 2012
  • Competition Patterns of Chinese LVP Companies (by Sales Volume or Value), 2011
  • Top 10 LVP Varieties and Output in China, 2011-2012
  • Proportion of LVP Sales Volume or Value (by Product) in China, 2011
  • Sales Volume / Value Growth Rate of Major LVP Varieties in China, 2007-2011
  • Regional Distribution of LVP (by Output) in China, 2011-2012
  • Major Varieties and Output of Fluid Balance Injection in China, 2010-2012
  • Major Varieties and Output of Therapeutic Injection in China, 2010-2012
  • Major Mannitol Injection Enterprises and Their Output in China, 2012
  • Bid Prices of Some National Essential Drugs in China, 2013
  • Major Fructose (10%, 500ml) Injection Enterprises and Their Output in China, 2011-2012
  • Major Glycerol and Fructose Sodium Chloride Injection (CO 250ml) Enterprises and Their Output in China, 2011-2012
  • Amino Acid Injection Varieties and Major Enterprises and Their Output in China, 2012
  • Major N (2)-L-propylamine acyl-L-glutamyl Injection Enterprises and Their Output in China, 2012
  • Purchase Costs of Imported N (2)-L-propylamine acyl-L-glutamyl of Typical Hospitals in 22 Chinese Cities, 2010-2012
  • Major Fat Emulsion Injection Enterprises and Their Output in China, 2012
  • Purchase Costs of Imported Fat Emulsion Injection of Typical Hospitals in 22 Chinese Cities, 2010-2012
  • Major Dextran Injection Enterprises and Their Output in China, 2012
  • Major Hydroxyethyl Starch Injection Enterprises and Their Output in China, 2012
  • Purchase Costs of Imported Hydroxyethyl Starch of Typical Hospitals in 22 Chinese Cities, 2010-2012
  • Purchase Costs of Peritoneal Dialysis Solution of Typical Hospitals in 22 Chinese Cities, 2010-2012
  • Major Peritoneal Dialysis Solution Enterprises and Their Output in China, 2012
  • Revenue and Profit of Kelun Pharma, 2008-2013
  • Revenue of Kelun Pharma (by Product) , 2008-2013
  • Revenue of Kelun (by Region), 2008-2013
  • Gross Margin of Kelun Pharma (by Product), 2008-2013
  • Kelun Pharma's Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
  • Kelun Pharma's Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2012
  • R & D Costs and % of Total Revenue of Kelun Pharma, 2011-2013
  • LVP Output, Sales Volume and Inventory of Kelun Pharma, 2011-2012
  • LVP Revenue and Gross Margin of Kelun Pharma, 2008-2013
  • LVP Revenue of Kelun (by Product), 2008-2013
  • Revenue and Net Income of Kelun Pharma, 2012-2015E
  • Revenue and Profit of China Resources Double-Crane, 2008-2013
  • Revenue of China Resources Double-Crane (by Product), 2008-2013
  • Revenue of China Resources Double-Crane (by Region), 2008-2013
  • Revenue of China Resources Double-Crane (by Product), 2008-2013
  • China Resources Double-Crane's Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
  • Name List and Revenue Contribution of Top 5 Clients of China Resources Double-Crane, H1 2013
  • Injection Output of China Resources Double-Crane, 2010-2012
  • Injection Revenue and Gross Margin of China Resources Double-Crane, 2008-2013
  • Progress of Online Projects of China Resources Double-Crane, by Jun 2013
  • Revenue and Net Income of China Resources Double-Crane, 2012-2015E
  • Revenue and Net Income of Fengyuan Pharmaceutical, 2008-2013
  • Revenue of Fengyuan Pharmaceutical (by Product), 2008-2013
  • Revenue of Fengyuan Pharmaceutical (by Region), 2008-2013
  • Gross Margin of Fengyuan Pharmaceutical (by Product), 2008-2013
  • Fengyuan Pharmaceutical's Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
  • Name List and Revenue Contribution of Top 5 Clients of Fengyuan Pharmaceutical, 2012-H1 2013
  • Fengyuan Pharmaceutical's Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2013
  • Name List and Procurement of Top 5 Suppliers of Fengyuan Pharmaceutical, 2012
  • LVP Output of Fengyuan Pharmaceutical, 2010-2012
  • Revenue and Net Income of Fengyuan Pharmaceutical , 2012-2015E
  • LVP Output, Sales Volume and Inventory of Huaren Pharmaceutical, 2011-2012
  • Revenue and Net Income of Huaren Pharmaceutical, 2008-2013
  • Revenue of Huaren Pharmaceutical (by Product), 2008-2013
  • Revenue of Huaren Pharmaceutical (by Region), 2008-2013
  • Revenue of Huaren Pharmaceutical (by Product), 2008-2013
  • Huaren Pharmaceutical's Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
  • Name List and Procurement of Top 5 Suppliers of Huaren Pharmaceutical, H1 2013
  • Huaren Pharmaceutical's Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2013
  • Name List and Revenue Contribution of Top 5 Clients of Huaren Pharmaceutical, H1 2013
  • R & D Costs and % of Total Revenue of Huaren Pharmaceutical, 2008-2013
  • Progress of Major R & D Projects of Huaren Pharmaceutical, by 2013
  • Revenue and Net Income of Huaren Pharmaceutical , 2012-2015E
  • Revenue and Net Income of Southwest Pharmaceutical, 2008-2013
  • Operating Revenue of Southwest Pharmaceutical (by Product), 2008-2013
  • Revenue of Southwest Pharmaceutical (by Region), 2008-2013
  • Gross Margin of Southwest Pharmaceutical (by Product), 2008-2013
  • Southwest Pharmaceutical's Revenue from Top 5 Clients and % of Total Revenue, 2008-2012
  • Name List and Revenue Contribution of Top 5 Clients of Southwest Pharmaceutical, 2012
  • LVP Revenue and Gross Margin of Southwest Pharmaceutical , 2008-2013
  • Injection Output of Southwest Pharmaceutical, 2010-2012
  • Revenue and Net Income of Southwest Pharmaceutical, 2012-2015E
  • Revenue of Lijun International Pharmaceutical (Holding), 2011-2013
  • Revenue of Shijiazhuang No.4 Pharmaceutical (by Product), 2011-2013
  • Gross Margin of Shijiazhuang No.4 Pharmaceutical , 2008-2013
  • Revenue and Net Income of Jin Jian Pharmaceutical, 2008-2013
  • LVP Output of Jin Jian Pharmaceutical, 2010-2012
  • Revenue and Gross Margin of Jin Jian Pharmaceutical, 2008-2013
  • Injection Output of Qingzhou Yaowang Medicine, 2010-2012
  • Injection Products and Prices of Qingzhou Yaowang Medicine
  • LVP Output of Dubang Pharmaceutical, 2010-2012
  • LVP Output of Shandong Lukang Cisen Pharmaceutical, 2010-2012
  • LVP Output of China Otsuka Pharmaceutical, 2010-2012
  • Major Injection Products of China Otsuka Pharmaceutical
  • Injection Output and Demand in China, 2012-2015E
  • Output of Top 10 Injection Producers in China, 2011-2012
  • LVP Revenue of Major Chinese Producers, 2008-2012
  • LVP Gross Margin of Major Chinese Producers, 2008-2013
  • Proportion of LVP Sales Volume or Value (by Product) in China, 2015E
Back to Top